Abstract
How can get structured therapies in metastatic cancer a source for detecting tumor-associated systems-biological processes as adjustable sizes available for biomodulatory therapies?
A therapy-derived methodological approach to explore tumor-associated systems biology should be explicated and developed by means of analyses of recently published biomodulatory therapy approaches introducing combined anti-inflammatory; angiostatic; and immunomodulatory therapy in the treatment for advanced chemorefractory tumors of quite different origin. Biomodulatory therapy approaches in tumors intend to develop systems-terms that provide a basis for broadening therapy-relevant capacities by regulating biological systems processes for tumor control. Combined targeted therapies of tumor-associated wound healing mechanisms, namely inflammation and neoangiogenesis, have shown that – using an approach for understanding systems biology as adjustable size – we may break through the barrier of complexity of tumor-stroma-interactions in a therapeutically relevant way. Targeting the tumor systems’ topology of aggregated action effects (inflammation, neoangiogenesis, Warburg effect, immune response, extracellular matrix remodeling, cell proliferation rate, apoptosis, coagulation effects) may open up the perspective of individualized tumor therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Vogt T, Hafner C, Bross K, et al (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98:2251–2256
Reichle A, Bross K, Vogt T, et al (2004) Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101:2247–2256
Reichle A, Bross K, Vogt T, et al (2004) Pioglitazone and rofecoxib combined with angiostatically scheduled capecitabine in far-advanced hepatobiliary carcinoma. Medimond S r l87–198
Reichle A, Vogt T, Kunz-Schughart L, et al (2006) Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans’ cell histiocytosis of adults. Br J Haematol 128:730–732
Reichle A, Grassinger J, Bross K, et al (2007) C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomark Insights 1:87–98
Reichle A, Vogt T, Coras B, et al (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17:360–364
Reichle A, Walter B, Berand A, et al (2007) Induction of complete remission in metastatic hormone-refractory prostate cancer: a combined anti-inflammatory therapy approach. J Clin Oncol 25
Ahn AC, Tewari M, Poon CS, et al (2006) The clinical applications of a systems approach. PLoS Med 3:e209
Ahn AC, Tewari M, Poon CS, et al (2006) The limits of reductionism in medicine: could systems biology offer an alternative? PLoS Med 3:e208
Field K, Lipton L (2007) Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 13:3806–3815
Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659
Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431:405–406
Mueller MM, Fusenig NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839–849
Angelo LS, Kurzrock R (2007) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13:2825–2830
Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229
Pabst T, Mueller BU (2007) Transcriptional dysregulation during myeloid transformation in AML. Oncogene 26:6829–6837
Setlur SR, Royce TE, Sboner A, et al (2007) Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67:10296–10303
Guillausseau PJ (2006) PROactive study. Lancet 367:23–27
Lincoff AM, Wolski K, Nicholls SJ, et al (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188
Rottlaender D, Michels G, Erdmann E, et al (2007) Therapy with glitazones – a risk for cardiovascular disease? Dtsch Med Wochenschr 132:2629–2632
Ogawa S, Lozach J, Benner C, et al (2005) Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122:707–721
Hafner C, Reichle A, Vogt T (2005) New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 5:393–419
Hafner C, Reichle A, Vogt T (2007) Davis DW. HRS, Abbruzzese JL (eds.) CP2. Conventional therapeutics with antiangiogenic activity. Antiangiogen Cancer Ther 5(6):301–327. Ref Type: Serial (Book,Monograph)
Kaipainen A, Kieran MW, Huang S, et al (2007) PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One 2:e260
Reichle A, Hildebrandt GC (2009) Principles of modular tumor therapy. Cancer Microenviron 2(Suppl 1):227–237
Reichle A (2009) Tumor systems need to be rendered usable for a new actiontheoretical abstraction: the starting point for novel therapeutic options. Curr Cancer Ther Rev 5: 232–242
Reichle A, Vogt T (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1:159–170
Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA, Wild PJ (2009) Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res 2009:848645
Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla FR, Califano A (2006) ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinform 7(Suppl 1):S7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Netherlands
About this chapter
Cite this chapter
Reichle, A. (2010). Uncovering Tumor Systems Biology by Biomodulatory Therapy Strategies. In: Reichle, A. (eds) From Molecular to Modular Tumor Therapy. The Tumor Microenvironment, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9531-2_23
Download citation
DOI: https://doi.org/10.1007/978-90-481-9531-2_23
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9530-5
Online ISBN: 978-90-481-9531-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)